TYMP and cancer: Notably, sublethal doses of vorinostat, far below the maximum serum concentrations reached with single agent therapy or in combination treatment in cancer patients, were able to significantly modulate TP expression within 24 h, suggesting that the enhanced lethality of the combination treatment could be primarily, if not exclusively, attributed to this mechanism.